(888) 645-1617

Avandia

The drug Avandia helps type 2 diabetes patients by making them more sensitive to insulin, but it has been linked to several side effects, including heart attacks. The FDA imposed restrictions on its use, but later removed them.

Avandia Pill

Dosage: 4-8 mg daily

Used to Treat: Type 2 diabetes

Related Drugs: Avandamet, Avandaryl

Manufacturer: GlaxoSmithKline

Black Box Warnings: Congestive heart failure

FDA Approval: Approved

View Lawsuit Information

*Please seek the advice of a medical professional before discontinuing the use of this drug.

Avandia (rosiglitazone) improves the way the body uses insulin by decreasing the amount of glucose released by the liver. It has been extensively studied, but drug maker GlaxoSmithKline (GSK) attempted to hide early research results that showed it might put patients at greater risk of heart problems than an alternative medication. At one time the U.S. Food and Drug Administration restricted Avandia’s use, but later, more extensive research failed to find those risks and the FDA removed the restrictions.

Avandia is a member of the class of medications called thiazolidinediones (TZD) or glitazones, which also includes Rezulin (troglitazone) and Actos (pioglitazone). Glitazones are known as “insulin sensitizers” because they make type 2 diabetes patients more sensitive to insulin, helping them to better maintain safe glucose levels.

Avandia is a Glitazone Insulin Sensitizer

Type 2 diabetes, which used to be known as adult-onset diabetes, is a condition in which the body either does not produce enough insulin or cannot effectively use what it does produce. Insulin is a hormone made in the pancreas that enables the cells of the body to use sugar (glucose). Without insulin, blood glucose levels can rise to abnormal levels – a condition called hyperglycemia which, in addition to causing increased thirst and a need to urinate frequently, can lead to medical emergencies such as diabetic ketoacidosis (DKA) and  hyperglycemic hyperosmolar nonketotic syndrome (HHNS, also referred to as hyperglycemic hyperosmolar state).

Avandia is also sold in combination with other medications as Avandamet (rosiglitazone/metformin) and Avandaryl (rosiglitazone/glimepiride). Typical starting dosage is 4 mg/day, which may be taken in two 2 mg doses, and maximum dosage is 8 mg/day, as prescribed by a doctor who monitors the patient’s response to the medication, including liver enzyme levels. The U.S. Food and Drug Administration (FDA) approved Avandia in 1999 for the treatment of Type 2 diabetes. No generic version of Avandia is available for sale in the U.S.

Avandia 2mg
Avandia 4mg
Avandia 8mg
Avandia comes in three sizes: 2mg, 4mg and 8mg

Avandia Warnings, Interactions and Side Effects

Avandia maker GlaxoSmithKline (GSK) provides warning labels to remind doctors and tell patients that Avandia “can cause fluid retention, which may exacerbate or lead to heart failure.” The fluid retention issues also mean “Avandia should be used with caution in patients with edema,” and fluid retention may be a cause of weight gain among patients taking Avandia. The makers also warn of “an increased incidence of bone fracture in patients, particularly female patients.”

In addition to the risk of heart failure, Avandia has several possible serious side effects that warrant immediate medical intervention:

  • Fast or pounding heartbeat
  • Changes in menstrual cycles
  • Bone fracture
  • Dark urine
  • Yellowing of the eyes or skin
  • Persistent nausea or vomiting
  • Abdominal pain
  • Vision problems, including color or night vision problems

Avandia may interact with medications that affect patients’ blood sugar levels, including insulin. In addition, beta blocker medications may keep diabetic patients from feeling the fast, pounding heartbeat they might feel when blood sugar levels get too low.

There are people who should  not take Avandia, including:

  • People with type 1 diabetes
  • Those with heart problems or heart failure
  • Diabetics with macular edema
  • Diabetics with liver problems
  • Pregnant diabetics
  • Premenopausal female diabetics
  • Breastfeeding mothers

The FDA put Avandia in Category C, drugs to avoid during pregnancy, because not enough research has been done to determine whether they’re safe. There’s no research on Avandia use by nursing mothers, but since clinical research found Avandia in the milk of lactating rats, nursing mothers should also avoid it.

Problems with Insulin Sensitizers

All three drugs in the thiazolidinedione family have had problems. Actos has been linked to an increased risk of heart failure and bladder cancer, but has not been recalled. The FDA approved Rezulin in 1997 but banned the drug in 2000 after it was shown to cause liver damage. Avandia use was severely restricted by the FDA in 2010 after it was linked to tens of thousands of heart attacks, strokes and heart failure. The FDA removed the restrictions in 2013, saying in a statement, “Although some scientific uncertainty about the cardiovascular safety of rosiglitazone medicines still remains, in light of the new re-evaluation of the Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes (RECORD) trial, our concern is substantially reduced.”

Bone Fracture Risks and Liver Toxicity

Avandia and Actos increase odds of non-spinal fracture

In addition to cardiac problems, a Swiss analysis of the records of British diabetic patients with fractures found “those on Avandia or Actos – known generically as rosiglitazone and pioglitazone – had double or triple the odds of non-spine fractures.The odds for fracture were increased among patients who took the drugs for approximately 12 to 18 months and the risk was highest for those with two or more years of therapy. Fractures of the hip and wrist were most notable.”

Avandia has also been implicated in liver failure. A 2009 study found 11 cases of liver failure associated with rosiglitazone and with pioglitazone among all cases of liver failure reported between 1997 and 2006.

Avandia’s History

The FDA approved SmithKline Beecham’s new medication Avandia in May 1999 for patients with type 2 diabetes.  A year and a half later, SmithKline Beecham merged with Glaxo Wellcome to become GlaxoSmithKline (GSK).

Meanwhile, in late 1999, SmithKline Beecham conducted a study to compare the risks of Avandia and Actos for heart patients.

“Not only was Avandia no better than Actos, but the study also provided clear signs that it was riskier to the heart,”

-the New York Times

Rather than publish the results, the company tried to bury them.

However, a legal settlement between GSK and the state of New York in 2004 required the drug maker to post details about all of its clinical trials. Cardiologist Steven Nissen completed a study using the company’s data that showed that Avandia increased heart attack risk by 43 percent. His peer-reviewed article appears in the June 2007 issue of the New England Journal of Medicine (NEJM). Later, it was revealed that Nissen was working for Takeda Pharmaceuticals — which manufactured Actos — when he authored his report.

The very next month, NEJM published GSK’s interim results of a study the FDA requested it conduct beginning in 2001. The RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes) study compared cardiovascular outcomes of Avandia to other commonly used diabetes drugs. The interim findings showed “no evidence of any increased mortality” from Avandia use, but “a significant increase in the risk of heart failure.”

Studies Show Avandia Tied to Increased Heart Failure

But the Nissen study had raised doubts in the public’s mind, and the lawsuits began. The first was filed on May 31, 2007 – a prospective class action lawsuit that, Law360 reported, was “brought by Celenio Cruz-Santana on behalf of himself and all similarly situated patients who took Avandia or related drugs Avandamet and Avandaryl, which are used to treat type 2 diabetes. The complaint alleged that GSK actively concealed information regarding the risks associated with the use of the drugs and misrepresented its products as safe for their intended use.”

The floodgates were open – thousands of patients followed Cruz-Santana’s example. In October 2007 the U.S. District Court consolidated the suits in a multidistrict litigation (MDL) in the Eastern District of Pennsylvania. Courts may use MDLs when lawsuits share similar characteristics. The court and the parties involved then choose one or more representative cases, called bellwether cases, and the results of those trials help the remaining plaintiffs and defendants decide how to proceed.

The cases came to the attention of the U.S. Senate Finance Committee in 2008. After two years of hearings it released a report accusing GSK of intimidating physicians, suppressing critics and hiding negative data while marketing Avandia.

More Avandia Studies

In light of the Nissen research, the FDA in November 2007 began requiring GSK to print a black box warning with Avandia’s packaging stressing its link to congestive heart failure.

Avandia Black-Box Warning

Meanwhile, researchers continued to study the drug’s effects. A non-randomized analysis of mortality data among elderly patients published in the Archives of Internal Medicine in November 2008 found results “compatible with an increased risk of all-cause mortality and congestive heart failure in patients initiating therapy with rosiglitazone [Avandia] compared with similar patients initiating therapy with pioglitazone [Actos].”

An analysis published in June 2010 in the Journal of the American Medical Association was similar to the November 2008 study and found similar results: “Compared with prescription of pioglitazone [Actos], prescription of rosiglitazone [Avandia] was associated with an increased risk of stroke, heart failure, and all-cause mortality and an increased risk of the composite of AMI, stroke, heart failure, or all-cause mortality in patients 65 years or older.”

Given those results, the FDA in September 2010 restricted Avandia sales to those already taking it and to new patients who enroll in the Avandia-Rosiglitazone Medicines Access Program. The European Medicines Agency went even further – it withdrew Avandia from the European market. But the FDA removed its restrictions in 2013 in light of more recent research.

Avandia Alternatives

Patients who wish to err on the side of caution have alternative medications they can ask their doctors about.

Actos (Pioglitazone)

Actos is a member of the thiazolidinedione family, making it the most similar drug to Avandia, and its pros and cons are similar too.

Glucophage (Metformin)

Avandia and Actos act as insulin sensitizers. Glucophage does too, but its main effect is to suppress glucose production in the liver. Metformin has been tested in humans since the 1950s and is relatively inexpensive.

Metformin is also available in combination with sulfonylureas, which increase insulin release in the pancreas, and with insulin itself.

DPP-4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) inhibitors have been around for about a decade. They help the body produce insulin when needed, and prevent the liver from releasing stored glucose into the blood. However, the FDA in 2015 warned that they “may cause joint pain that can be severe and disabling.”

While Avandia is an effective medication for many type 2 diabetes patients, it has caused problems for others, most seriously in the areas of cardiovascular death, severe liver toxicity and increased risk of bone fractures. Anyone considering Avandia should be aware of warnings about possible side effects, and consider its benefits against those of possible alternatives.

View Sources
  1. Rosiglitazone. (2016, June 16). MedlinePlus. Retrieved from https://medlineplus.gov/druginfo/meds/a699023.html
  2. Avandia. Drugs.com. Retrieved from https://www.drugs.com/avandia.html
  3. Avandia. WebMD. Retrieved from http://www.webmd.com/drugs/2/drug-17300/avandia-oral/details
  4. Type 2 diabetes. American Diabetes Association. Retrieved from http://www.diabetes.org/diabetes-basics/type-2/
  5. Diabetes drugs (glitazones) double fracture risk: Swiss study. (2008, April 29). Reuters. Retrieved from http://www.natap.org/2008/HIV/050108_01.htm
  6. FDA Lifts Prescribing Restrictions on Avandia. (2013, November 28). Diabetes in Control Retrieved from http://www.diabetesincontrol.com/fda-lifts-prescribing-restrictions-on-avandia/
  7. Meier, Christian et al. (2008, April 28). Use of Thiazolidinediones and Fracture Risk. Archives of Internal Medicine. Retrieved from https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/414172
  8. Floyd, James S. et al. (2009, July 22). Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiology & Drug Safety. Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/pds.1804/abstract
  9. Graham, David J. et al. (2010, June 28). Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. Journal of the American Medical Association. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20584880
  10. Winkelmayer, WC et al. (2008 November). Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Archives of Internal Medicine. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/19029503
  11. Conrad Stöppler, Melissa, MD. (2016, October 7). Hyperglycemia (High Blood Sugar). Retrieved from http://www.medicinenet.com/hyperglycemia/article.htm
  12. Harris, Gardiner. (2010, July 13). Diabetes Drug Maker Hid Test Data, Files Indicate. New York Times. Retrieved from http://www.nytimes.com/2010/07/13/health/policy/13avandia.html
  13. Harris, Gardiner. (2010, July 9). Caustic Government Report Deals Blow to Diabetes Drug. New York Times. Retrieved from http://www.nytimes.com/2010/07/10/health/10diabetes.html
  14. Harris, Gardiner. (2010, September 23). F.D.A. to Restrict Avandia, Citing Heart Risk. New York Times. Retrieved from http://www.nytimes.com/2010/09/24/health/policy/24avandia.html
  15. Timeline: The story of Avandia. (2010, July 16). WNET.org. Retrieved from http://www.pbs.org/wnet/need-to-know/health/timeline-history-of-avandia/2314/#1
  16. Nissen, Steven E and Wolski, Kathy. (2007, June 14). Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. New England Journal of Medicine. Retrieved from http://www.nejm.org/doi/full/10.1056/NEJMoa072761#t=article
  17. Home, Philip D. et al. (2007, July 5). Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis. New England Journal of Medicine. Retrieved from http://www.nejm.org/doi/full/10.1056/NEJMoa073394#t=article
  18. Daly, Erin Marie. (2007, June 1). Glaxo Slapped With Avandia Personal Injury Suit. Law360. Retrieved from https://www.law360.com/articles/25924/glaxo-slapped-with-avandia-personal-injury-suit
  19. Avandia Lawsuit Settlement of $60M Will Resolve 700 Cases: Report. (2010, May 11). AboutLawsuits.com. Retrieved from http://www.aboutlawsuits.com/avandia-lawsuit-settlement-reached-in-cases-10153/
  20. Settlement of Avandia Lawsuits Reached in About 10,000 More Cases. (2010, July 14). AboutLawsuits.com. Retrieved from http://www.aboutlawsuits.com/settlement-avandia-lawsuits-reached-more-cases-11426/
  21. FDA requires removal of certain restrictions on the diabetes drug Avandia. (2013, November 25). U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/
  22. Avandia Side Effects Center. (2017, February 16). RxList.com. Retrieved from http://www.rxlist.com/avandia-side-effects-drug-center.htm
  23. Avandia. Diabetes.co.uk. Retrieved from http://www.diabetes.co.uk/Diabetes-and-Avandia.html
  24. Rice, Sabriya. (2010, September 10). Concerned about Avandia? Here are other options. CNN. Retrieved from http://www.cnn.com/2010/HEALTH/09/23/avandia.alternatives.diabetes/
  25. U.S. Food and Drug Administration. (2015, August 28). FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Retrieved from https://www.fda.gov/Drugs/DrugSafety/ucm459579.htm